Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Atriva Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the acquisition, Atriva aims to develop novel, highly efficacious and safe therapies for the treatment of severe diseases caused by RNA-viruses, including ATR-002 (zapnometinib), a first-in-class, host-targeting agent that aims to inhibit viral r...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 18, 2023
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Atriva Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
